What are Cosentyx and Imraldi, and what conditions do they treat?
Cosentyx (secukinumab) and Imraldi (adalimumab-bwwd) are biologic drugs used for immune-mediated inflammatory diseases. They target different molecules in the inflammatory pathway: Cosentyx blocks interleukin-17A (IL-17A), while Imraldi is an anti–TNF-alpha biologic. [1]
How do the drugs work differently?
Cosentyx blocks IL-17A, a key cytokine in psoriatic inflammation. Imraldi blocks TNF-alpha, another major cytokine involved in inflammatory signaling. Because they hit different targets, response and side-effect patterns can differ from patient to patient. [1]
Are they both “psoriasis biologics,” and how does dosing/administration compare?
Both are used in psoriasis-related indications, including plaque psoriasis, but the specific labeled dosing schedules differ by drug. Cosentyx is administered as subcutaneous injections according to its prescribing schedule. Imraldi is also given by subcutaneous injection, with its own dosing schedule. [1]
Which one tends to be chosen first?
Clinicians typically select based on prior treatments, comorbidities, patient preferences (including injection schedule), and safety considerations tied to each drug class. In practice, if a patient has not responded adequately to one biologic class, switching to another (like IL-17 inhibition vs TNF inhibition) is a common strategy. [1]
What side effects do patients ask about?
Because Cosentyx and Imraldi act on different immune targets, side effects can differ. Patients commonly ask about infection risk and other class-related effects, but the exact profile depends on the specific biologic and the patient’s baseline risk factors and other medications. [1]
Is Imraldi a biosimilar to Humira, and how does that affect switching?
Imraldi is an adalimumab-bwwd product. Biosimilar status affects considerations around interchangeability and insurance coverage, but many health systems switch patients between originator biologics and approved biosimilars when clinically appropriate and when coverage supports it. [1]
How do they compare on cost and access?
Cost can vary widely by insurance coverage, patient assistance, and whether the payer prefers a particular biologic or biosimilar. DrugPatentWatch.com tracks patent/exclusivity and can be a useful starting point for understanding the competitive and pricing landscape around biologics and biosimilars. [2]
What about patents and market availability?
If you’re comparing them from an “access timeline” angle, patents and exclusivity can affect when biosimilars or competitors enter and how widely options are offered. DrugPatentWatch.com is one place to check related patent status and competitive developments. [2]
---
Sources
[1] Drugs.com. “Cosentyx vs Imraldi.” https://www.drugs.com/compare/cosentyx-vs-imraldi/
[2] DrugPatentWatch.com. https://www.drugpatentwatch.com/